Li Yan, a deputy to the 13th National People's Congress, and also president of Qilu Pharmaceutical Group [Photo/Iqilu News]

Li Yan, a deputy to the 13th National People's Congress, and also president of Qilu Pharmaceutical Group brought her suggestions on China's national pharmaceutical industry development during the ongoing two sessions, the annual meetings of China's top legislature and political advisory body.

In her proposal, Li called for more support for the innovation and upgrading of the national pharmaceutical industry.

In recent years, China has seen great progress in the innovation of the pharmaceutical industry. "With the growing number of talents in the biomedical industry, it is believed that in the next few years, a large number of innovative achievements will continue to emerge," Li said. "The overall innovation will better serve clinical application."

Li also suggested to further strengthen industry-university-research cooperation.

According to Li, at present, the cooperation between industry and universities needs to be enhanced. "In addition to investing in research, we should consider how to better combine the research achievements with medical industries and how to transform the cutting-edge research results into productivity."

During the cooperation between enterprises and universities, more efforts should be made to deal with the benefit distribution relationship and the contradiction in intellectual property rights, Li added.

Li also called for social media outlets to give more positive reports on domestic drugs, using examples to enhance people's confidence and support domestic medicine to promote national pharmaceutical brands.